Patterns of Clinical Presenations of Thrombotic Thrombocytopenic Purpura in Plasma Exchange Era

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4642-4642 ◽  
Author(s):  
Muath Dawod ◽  
Mohammad Alhyari ◽  
Philip Kuriakose

Abstract Abstract 4642 Thrombotic thrombocytopenic purpura (TTP) is a rare but serious disease in which early diagnosis and management has a major impact on outcome. TTP has been historically linked to a pentad of clinical features (mental status changes, fever, acute renal failure, anemia and thrombocytopenia). The frequency of the classical pentand in the pre plasma exchange era has been reported to be as high as 40 percent. With the introduction of plasma exchange and increased awareness of this disease a different pattern of clinical presentation of TTP might be forming based on early diagnosis. We reviewed the clinical presentation of 91 patients with a diagnosis of TTP in terms of pattern and duration of symptoms. Only 9% of patients (n=8) presented with the pentad. Duration of symptoms in all patients ranged between 1 and 60 days, with a mean of 9.3 days. Statistical analysis showed no correlation between the duration of symptoms prior to diagnosis and the presence of the pentand (mean of symptom duration in the pentad and non-pentad groups were 9.4 and 9.3 days with range of (3–30) and (1–60), respectively). The most common patterns of clinical presentation were in the form of constitutional symptoms (fatigue, malaise and generalized weakness), which were seen in 67% of patients (n=60), followed by neurological symptoms (mainly headache and confusion) in 51% of pateints (n=46). Gastrointestinal (GI) symptoms (nausea, vomiting or abdominal pain) were seen in 47% of patients (n=42). The most common triad of symptoms was neurological (headache and confusion), constitutional (fatigue, weakness and anorexia) and GI(nausea, vomiting and abdominal pain), which was present in 14% of patients (n=13). In terms of clinical outcome, there was also no correlation between the duration of symptoms and the clinical outcome (mean of symptom duration in the alive and dead groups were 9.2 and 10 days, with range of 1–60 and 1–21 days, respectively). There was no association between the presence or absence of the pentad and mortality, (25% (n=2/8) as compared to 11% (n=9/83), P-value of 0.248). On the other hand patients with poor outcome (defined as death) were less likely to present with constitutional and nonspecfic symptoms (27.3% (n=3/11) as compared to 72.5% (n=58/80), P-value of 0.005), As a conclusion, the pentad is a very rare presentation in TTP and the duration of symptoms prior to diagnosis does not predict its presence. While nonspecific and/or constitutional symptoms are the most common presentation, patients who do not present with such symptoms tend to do worse. Our study highlights the importance of defining the clinical presentation of this disease in a new and pertinent form that could help clinicians in the diagnosis and timely management. It also raises the question of prognsotic value of the clinical presentation in this potentially lethal disease. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4915-4915
Author(s):  
Shahid Iqbal ◽  
Syed Ziauddin A. Zaidi ◽  
Ibraheem H. Motabi ◽  
Nawal Faiez Alshehry ◽  
Mubarak S. AlGhamdi ◽  
...  

Abstract Background Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by microvascular platelet deposition and thrombus formation with resulting microangiopathic hemolytic anemia and thrombocytopenia. Deficiency of the von Willebrand factor cleavage metalloprotease, also known as ADAMTS 13, has been implicated as an important etiological factor in TTP. Few small studies have been reported on Saudi patients with TTP until now. Our aim was to analyze the clinical features, laboratory characteristics and treatment outcomes with TTP patients treated at our large tertiary care center. Methods This is retrospective data of 24 patients with diagnosed of TTP who were treated at King Fahad Medical City, Riyadh, Saudi Arabia between October 2006 and April 2015. Patient suspected as a case of TTP on the basis of clinical features with the evidence of microangiopathic hemolysis and thrombocytopenia were included in this study although data related to pentad of TTP was collected and wherever logistically possible ADAMTS13 levels and inhibitor titer were determined. The primary aim was outcome assessment by overall response rate (ORR) in the treated patients through Kaplan-Meier method. Paired sample t-test was applied to determine the mean significant difference among platelets (plt), hemoglobin (Hgb) & LDH on day 1 and day 7 of treatment. Results Twenty-four TTP patients (18 females; 6 males) admitted to our hospital from 2006 to 2015 were analyzed. The mean age was 33.5±13.9 years. Twenty-two (91%) of the patients presented with neurologic features, seven (29%) had fever, ten (42%) had renal impairment that normalized with treatment and four (20.83%) had increased troponin-T or cardiac symptoms. There were 22 patients (91.7%) with the triad of TTP, including hemolytic anemia, thrombocytopenia and neurologic abnormalities; only 2 (8.2%) had the classical pentad of TTP. Among the plausible etiology, idiopathic (51.8%) was the most common followed by acquired autoimmune abnormalities (29.2%). Plasma ADAMTS 13 activity was determined in 19 patients. Eight patients (42.1%) had severe ADAMTS 13 deficiency (activity< 5%); 5 (26.3%) had moderate decrease of ADAMTS 13 activity (activity: 5-10%); another 3 (15.8%) had low ADAMTS 13 activity and 3 (15.8%) patients had normal ADAMTS 13 (>50%) most likely due to sampling post plasma infusion in emergency situations. Median platelet count on Day 1 was 14x10^9/L, and Day 7 was 119x10^9/L (P value< 0.001), Median Hgb on Day1 was 8.25 gm/dl and Day 7 was 9.35 gm/dl (P value< 0.007), Median LDH on Day 1 was 1211 IU/L and Day7 was 278.92 IU/L (P value< 0.001) respectively. All patients received plasma exchange whereas 23 (95.8%) patients received adjunctive corticosteroids. Five patients (20.8%) were early refractory to standard treatment with therapeutic plasma exchange (TPE). Thirteen (54.2%) patients received rituximab either due to refractoriness to TPE on ~ day 7, or earlier due to cardiac or neurological manifestations at treating physician's discretion. Average hospital stay was 27 days (range 1-131). Twenty-one out of 24 (87.5%) achieved complete remission (CR) without any subsequent relapse. On long term follow up of 22 months (median, Range 1-113), overall survival was 80%. Three patients died during acute episode because of very sever disease or delayed arrival to our center. One patient died later on because of other comorbidities while in CR. Conclusion Thrombotic thrombocytopenic purpura is a life threatening condition and immediate treatment with plasma exchange along with steroids and or rituximab was very effective in preventing high risk of mortality and achieving durable CR in 87.5% of our patients. Combination of very severe CNS manifestations and delayed arrival contributed to mortality significantly. More awareness is needed for early diagnosis and early referral to higher centers. Disclosures No relevant conflicts of interest to declare.


1999 ◽  
Vol 102 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Javier de la Rubia ◽  
Aurelio López ◽  
Francisco Arriaga ◽  
Ana Rosa Cid ◽  
Ana Isabel Vicente ◽  
...  

2020 ◽  
Vol 13 (3) ◽  
pp. 1368-1372
Author(s):  
Umit Yavuz Malkan ◽  
Murat Albayrak ◽  
Hacer Berna Ozturk ◽  
Merih Reis Aras ◽  
Bugra Saglam ◽  
...  

Microangiopathic hemolytic anemia (MAHA) can be observed as a paraneoplastic syndrome (PS) in certain tumors. MAHA-related signet ring cell carcinoma (SRCC) of an unknown origin is very infrequent. Herein we present a SRCC case presented with refractory acquired thrombotic thrombocytopenic purpura (TTP). A 35-year-old man applied to the emergency service with fatigue and headache. His laboratory tests resulted as white blood cell 9,020/µL, hemoglobin 3.5 g/dL, platelet 18,000/µL. Schistocytes, micro-spherocytes, and thrombocytopenia were observed in his blood smear. MAHA was present and he was considered as having TTP. Plasma exchange treatment was initiated; however, he was refractory to this treatment. Thorax and abdomen computerized tomography revealed thickening of minor curvature in stomach corpus with hepatogastric and paraceliac lymphadenopathy. Bone marrow (BM) investigation by our clinic resulted as the metastasis of adenocarcinoma. Ulceration and necrosis were observed by gastric endoscopy procedure. Biopsy was taken during endoscopic intervention, which resulted as SRCC. MAHA may be seen as a PS in some tumors, especially gastric cancers. Tumor-related MAHA is generally accompanied by BM metastases. As a result, BM investigation may be used as the main diagnostic method to find the underlying cancer. The clinical course of cases with tumor-related MAHA is usually poor, and these cases are usually refractory to plasma exchange treatment. In conclusion, physicians should suspect a malignancy and BM involvement when faced with a case of refractory TTP.


1990 ◽  
Vol 84 (4) ◽  
pp. 209-211
Author(s):  
Yoshitoshi Itoh ◽  
Tomoyuki Taniguchi ◽  
Naoshi Takeyama ◽  
Hideki Kuriki ◽  
Takaya Tanaka

Sign in / Sign up

Export Citation Format

Share Document